SCHEMBL12480748

SCHEMBL12480748

ON=Cc1ccnc(Cl)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.38
KMT2A Q03164 4/20 0.38
KDM4E B2RXH2 4/20 0.38
HPGD P15428 4/20 0.35
TSHR P16473 2/20 0.35
NPC1 O15118 4/20 0.34
RAB9A P51151 4/20 0.34
PKM P14618 4/20 0.34
ALDH1A1 P00352 5/20 0.33
LMNA P02545 4/20 0.33
MAPT P10636 4/20 0.33
MEN1 O00255 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
USP2 O75604 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12480745 1.00 L3MBTL1 (0.38) L3MBTL1KMT2AKDM4EHPGDTSHR
SCHEMBL845896 0.81 HPGD (0.37) L3MBTL1KMT2AKDM4EHPGDTSHR
SCHEMBL845897 0.81 HPGD (0.37) L3MBTL1KMT2AKDM4EHPGDTSHR
SCHEMBL26617038 0.78 HPGD (0.35) L3MBTL1KDM4EHPGDTSHRNPC1
SCHEMBL29953562 0.76 CCR1 (0.47) KMT2ANPC1RAB9APKMALDH1A1
SCHEMBL1637824 0.76 CCR1 (0.47) KMT2ANPC1RAB9APKMALDH1A1
SCHEMBL12479704 0.75 HTT (0.33) L3MBTL1ALDH1A1LMNAMAPTUSP2
SCHEMBL845890 0.75 CCR1 (0.39) L3MBTL1KMT2AKDM4EHPGDTSHR
SCHEMBL845889 0.75 CCR1 (0.39) L3MBTL1KMT2AKDM4EHPGDTSHR
SCHEMBL12479706 0.75 HTT (0.33) L3MBTL1ALDH1A1LMNAMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 US disclosed
EP-2661433-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) Novartis AG (CH) 2013-11-13 EP disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 US disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 L3MBTL1 4875/4885KMT2A 4723/4885KDM4E 4092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.